In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
about
Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadineExtrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.Summary of information on human CYP enzymes: human P450 metabolism data.A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction predictionHuman drug metabolism and the cytochromes P450: application and relevance of in vitro models.Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique.Elucidating mechanisms of drug-induced toxicity.Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?Drug interactions important for periodontal therapy.Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability.Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites.Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.Drug-drug noninteractions.Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses.High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes.Effect of botanical immunomodulators on human CYP3A4 inhibition: implications for concurrent use as adjuvants in cancer therapy.Mechanism of cytochrome P450-3A inhibition by ketoconazole.The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes.Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat.Effects of propofol on human hepatic microsomal cytochrome P450 activities.Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine.
P2860
Q24564979-4D7AEA2D-DB23-46CF-8720-85AF90DFFA5CQ30577448-92DCFBF5-7E5F-4457-85C6-03E94B55CC1EQ32103802-0D03CDAB-85CB-4C50-93C4-BE8EBB08C496Q33383326-D8BF1F04-580B-4B01-B7E6-09B5D1EE1E18Q34430456-2222B833-3982-497D-9C94-90C5FEB3B0D7Q35827223-17081F47-2015-4E17-AC7D-FFF456D28FACQ35846680-221D1D88-336F-4EEE-BC75-A7E2AF7E78DDQ36111915-B04B8FF7-7F2C-4F3B-8D4C-89890EB2BA53Q36159074-C1F96D1D-5E53-4CF8-ACE4-D4C53ED86EA4Q36809156-6D0D6DE6-ACF9-4C2E-8CEE-E35C4D4A979DQ37717622-42856F3D-F86C-4955-B7AA-D913D663F6A7Q37780212-F4EDF891-298D-4F9E-AE18-D06CA958D748Q38107523-488D986A-8405-4C58-B43A-95ACCF067EFFQ39118138-2101D6BF-C79B-4385-8C80-19CAA1212A21Q39770558-A8A6E3E8-75A2-4B46-AD3A-1C7264122C3AQ40632369-A56E1EC3-CAC2-457A-8355-2CB648A3745DQ43244938-A285AC70-D34B-49BA-A4E2-0E0C33A71121Q43554157-C19CD51B-45B0-4D95-A2F9-D8065AD521E6Q44316235-44A35013-83DF-4A23-AEBE-9DD222138EEDQ44560574-AEAD51FF-6045-4567-B4D7-738321F8ECA5Q45194833-0069E01E-944B-4A12-A49D-A03A11E6A54EQ45344293-93202B61-1451-41F0-BAAB-BFBB6A263D4CQ46107321-AB5BE2F7-749D-4AF0-8732-8AC0523F8664Q46848805-60F29FC9-3E78-4EAA-BC5C-47313900FE76Q50179674-3F34F99D-F092-4816-A838-8D6825C0B1F6Q51469186-C5B88081-AA57-40A5-8309-F96CA8CB2292Q51499258-5437D3ED-51D1-4BBE-9BFD-9E682B226406Q51562990-5F0031A6-BC3A-46C5-8AA1-7443C1161452Q52041523-E53CED15-DEDB-4CCD-A99A-9FFE81CF2592Q53937336-545C6CF8-63AA-4812-92D9-8F3A13104212
P2860
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
@en
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
@nl
type
label
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
@en
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
@nl
prefLabel
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
@en
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
@nl
P2093
P2860
P1476
In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
@en
P2093
Greenblatt DJ
Harmatz JS
von Moltke LL
P2860
P304
P356
10.1002/J.1552-4604.1994.TB04735.X
P577
1994-12-01T00:00:00Z